Protalix BioTherapeutics, Inc.PLX
What Protalix BioTherapeutics, Inc. does.
We are a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension. ProCellEx®, our unique, proprietary plant cell-based protein expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
Our corporate strategy includes development of treatments for rare and orphan diseases. To execute on our strategy, we are turning our focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. We believe our treatments of interest will address both genetic and non-genetic diseases. We currently intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities.
Consistent with this strategy, we are developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and a number of other technologies and preclinical assets. We have completed a Phase 1 First-in-Human clinical trial of PRX-115. Currently, we are actively recruiting for, and the first patients have been randomized in a Phase 2 clinical trial of PRX-115 for the treatment of uncontrolled gout which we refer to as the RELEASE study.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $62.9M | $38.4M | $47.6M | $65.5M | $53.4M | $52.7M |
| Net income | -$6.5M | -$27.6M | -$14.9M | $8.3M | $2.9M | -$6.6M |
| Free cash flow | -$26.8M | -$11.7M | -$25.6M | -$2.5M | $7.4M | -$13.6M |
More on PLX.
- Protalix BioTherapeutics, Inc. summary
- Protalix BioTherapeutics, Inc. financial statements
- Protalix BioTherapeutics, Inc. key metrics
- Protalix BioTherapeutics, Inc. health scores and style box
- Protalix BioTherapeutics, Inc. earnings
- Protalix BioTherapeutics, Inc. dividends
- Protalix BioTherapeutics, Inc. valuation
- Protalix BioTherapeutics, Inc. ownership and insiders
- Protalix BioTherapeutics, Inc. peers
Figures from Protalix BioTherapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.